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Objective: Pathogenic variants in KCNB1, encoding the voltage-gated potassium channel KV2.1, are associated with
developmental and epileptic encephalopathy (DEE). Previous functional studies on a limited number of KCNB1 variants
indicated a range of molecular mechanisms by which variants affect channel function, including loss of voltage sensitiv-
ity, loss of ion selectivity, and reduced cell-surface expression.
Methods: We evaluated a series of 17 KCNB1 variants associated with DEE or other neurodevelopmental disorders
(NDDs) to rapidly ascertain channel dysfunction using high-throughput functional assays. Specifically, we investigated
the biophysical properties and cell-surface expression of variant KV2.1 channels expressed in heterologous cells using
high-throughput automated electrophysiology and immunocytochemistry–flow cytometry.
Results: Pathogenic variants exhibited diverse functional defects, including altered current density and shifts in the
voltage dependence of activation and/or inactivation, as homotetramers or when coexpressed with wild-type KV2.1.
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Quantification of protein expression also identified variants with reduced total KV2.1 expression or deficient cell-surface
expression.
Interpretation: Our study establishes a platform for rapid screening of KV2.1 functional defects caused by KCNB1 vari-
ants associated with DEE and other NDDs. This will aid in establishing KCNB1 variant pathogenicity and the mechanism
of dysfunction, which will enable targeted strategies for therapeutic intervention based on molecular phenotype.
ANN NEUROL 2019;86:899–912
De novo variants in a diverse range of genes constitute asignificant cause of developmental and epileptic enceph-
alopathy (DEE) and other neurodevelopmental disorders
(NDDs).1,2 Despite an increasing number of genes identified
for DEE and increased clinical genetic testing, many variants
are classified as variants of uncertain significance that are diffi-
cult to interpret and/or act on. Obtaining functional data is a
powerful approach to bridge the knowledge gap between
genetics and molecular pathology,3 which can provide addi-
tional evidence for interpretation of variant pathogenicity and
offer functional information to guide treatment strategies.
However, due to the low throughput of many functional
assays, functional annotation of variants is a major bottleneck
in the field. The development of high-throughput assays is a
necessary step for experimental evaluation of the large volume
of novel variants being identified by increased clinical genetic
testing.
KCNB1 (NM004975) encodes the KV2.1 voltage-gated
potassium (K+) channel α-subunit that conducts delayed rec-
tifier K+ current,4 a key modulator of membrane repolariza-
tion in electrically excitable cells, including various neuron
subtypes.5 Kcnb1-deficient mice display enhanced seizure sus-
ceptibility and behavioral hyperexcitability, indicating that
KV2.1 acts as a homeostatic suppressor of heightened neuro-
nal activity.6 De novo missense variants in KCNB1 are associ-
ated with DEE,7–13 which includes multiple seizure types,
developmental delay, and neuropsychiatric sequelae. Correla-
tional analyses based solely on the substituted amino acid type
and position have proven insufficient for genotype–phenotype
association,11 highlighting the need for experimental studies
to determine functional effects of additional variants. To date,
7 KCNB1 variants associated with DEE, all located in the
pore (S347R, T374I, V378A, G379R, G401R) and voltage-
sensor (I199F, R306C) domains, have been shown to exhibit
altered potassium current density, voltage dependence, and/or
ion selectivity.7–9,14 However, determining the functional
consequences of a larger series of variants is necessary to define
the range of dysfunction and broaden the associated clinical
phenotypes studied.
In this study, we performed high-throughput functional
studies of 19 KCNB1 variants (17 missense, 1 frameshift,
1 nonsense) to determine their effect on protein function and
provide functional evidence for weighing potential pathoge-
nicity. Several broad categories of channel dysfunction (ie,
altered peak current density, voltage dependence, protein
expression) were identified, and most variants conferred some
degree of loss of function. Our results provide insight into
functional pathogenicity for a large series of KCNB1 variants.
This will aid in prioritization for development of more com-
plex experimental models (ie, knockin mouse or induced plu-
ripotent stem cells) by identifying a subset of representative
variants based on underlying pathophysiologic mechanisms.
Uncovering a range of KCNB1 functional defects will help
define genotype–phenotype relationships by adding a molecu-
lar phenotype to the genotypes, and may ultimately enable
development of targeted treatment strategies for individuals
with KCNB1 DEE.
Materials and Methods
Information was collected for individuals with DEE or other
NDDs and a potentially pathogenicKCNB1 variant (identified
as part of routine care) under approval of the Ann & Robert
H. Lurie Children’s Hospital of Chicago Institutional Review
Board (IRB) or through collection of deidentified information
deemed non–human subjects research by the Northwestern
University IRB. Consent for release of deidentified informa-
tion was obtained in accordance with local institutional poli-
cies. In addition, 11 KCNB1 variants were obtained from the
literature and variant databases.8–13,15–19 No functional studies
were available for 17 of 19 variants.
Plasmids
Full-length humanKCNB1 cDNA in plasmid pIRES2-DsRed-MST-
KV2.1-WT (Addgene, Cambridge, MA; #131707) was described.
7,14
For cotransfections, pIRES2-smGFP-KV2.1-WT (Addgene
#131709) was engineered by replacingDsRed-MSTwith smGFP, all-
owing detection of WT + variant cells (Addgene #131709). For cell-
surface labeling, a 2xHA-tag was inserted between amino acids
220 and 221, and the IRES2-DsRed-MST cassette was removed,
resulting in pCMV-KV2.1-HA-WT. Variants were introduced using
QuikChange mutagenesis (Agilent Technologies, Santa Clara, CA).
Clones were sequenced to confirm desired modifications and absence
of unwantedmutations.
Heterologous Expression
Transient expression of wild-type (WT) and variant KV2.1 in CHO-
K1 cells (CRL 9618; ATCC, Manassas, VA) was achieved by electro-
poration using the STX system (MaxCyte, Gaithersburg, MD) with
the preset CHO or CHO-PE protocol (7.5–10μg KCNB1 cDNA
per 1e7 cells). Following electroporation, cells were grown for 36 hours,
harvested, and frozen in liquid N2. Coexpression of WT and variant
was achieved by coelectroporation of pIRES2-DsRed-MST-
KV2.1-WT or -variant (5μg) plus pIRES2-smGFP-KV2.1-WT
(5μg).
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Cell Preparation for Automated Patch Clamp
Recording
Cells were thawed, incubated for 24 hours, and harvested using
0.25% trypsin–ethylenediaminetetraacetic acid in F-12K media
(GIBCO/Invitrogen, Waltham, MA) supplemented with 10%
fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA).
Cell number and viability were determined (Vi-Cell; Beckman
Coulter, Fullerton, CA). Cells were diluted to 200,000cells/ml
with external solution (see below) and allowed to recover for
40 minutes at 15C, shaking at 200rpm.
Automated Patch Clamp Recording
Automated patch clamp recording was performed using the
SyncroPatch 768PE system (Nanion Technologies, Munich, Ger-
many). External solution contained (in mM): 140 NaCl, 4 KCl,
1 MgCl2, 2 CaCl2, 5 glucose, and 10 hydroxyethylpiperazine ethane
sulfonic acid (HEPES), pH 7.4. Internal solution contained (in mM):
60 KF, 50 KCl, 10 NaCl, 20 ethyleneglycoltetraacetic acid,
10 HEPES, pH 7.2. Pulse generation and data collection used
PatchController 384 V1.3.0 and DataController384 V1.2.1 software
(Nanion Technologies). Whole-cell currents were acquired at 5kHz
and filtered at 1kHz. Currents were not leak subtracted. Access resis-
tance and apparent membrane capacitance were estimated using built-
in protocols. Whole-cell currents were measured at room temperature
from a holding potential of −80mV and elicited with depolarizing
steps (500milliseconds) from−100 to +60mV (10mV steps) followed
by a 250-millisecond step to −30mV or 0mV (tail currents). Back-
ground currents were removed by digital subtraction of whole-cell cur-
rents recorded from nontransfected CHO-K1 cells offline. Current
amplitudes were analyzed from all cells with seal resistance ≥0.5GΩ,
series resistance ≤20MΩ, and cell capacitance >2pF. Electrically unsta-
ble cells with loss of seal or voltage control were excluded. The peak
current (Ipeak) was normalized for cell capacitance and plotted against
voltage to generate current density–voltage relationships. Voltage
dependence of activation was determined by plotting tail currents nor-
malized to the largest tail current amplitude against the depolarizing
test potential (−100 to +60 mV). Normalized G-V curves were fit
with the Boltzmann functionG = 1 / (1 + exp[(V−V½) / k]) to deter-
mine voltage for half-maximal channel activation (V½) and slope fac-
tor (k). Voltage dependence of inactivation was assessed following a
5-second prepulse from &minus;100 to +40mV (10mV steps)
followed by a 250-millisecond step to +60mV. Normalized currents
measured at the +60mV test potential were plotted against the
prepulse voltage and fit with the Boltzmann function (I/Imax = 1 / (1
+ exp[(V − V½) / k]) to determine V½ and k. Voltage dependence of
channel activation or inactivation was determined only from cells with
positive outward current values following background subtraction.
Statistical outliers (≥  3 standard deviations) were excluded.
Immunocytochemistry–Flow Cytometry
Cells were electroporated as described above and incubated for
24 hours prior to labeling. For analysis of total and cell-surface
expression, cells were incubated with αHA-Alexa488 (16B12;
Thermo Fisher Scientific, Waltham, MA; 1:250 in fluorescence-
activated cell sorting buffer [1% fetal bovine serum, 0.05% NaN3 in
phosphate-buffered saline, pH 7.4]). Cells were then harvested and
fixed/permeabilized using Fix&Perm buffer (BDBiosciences, Franklin
Lakes, NJ). Following permeabilization, KV2.1 was detected using
Alexa 647–conjugated anti-KV2.1 mouse monoclonal antibody
(K89/34, Antibodies Incorporated, Davis, CA; A20186, Thermo
Fisher Scientific; 1:200 in Perm buffer with 3% normal goat serum).
Fluorescence signals were measured by flow cytometry (CytoFlex,
Beckman Coulter) and analyzed with CytExpert (Beckman Coulter)
and FlowJo software (FlowJo, Ashland, OR). Nontransfected CHO-
K1 cells processed identically served as negative controls. Light-scatter
based gates (forward scatter/side scatter (FSC/SSC)) were used to
exclude nonviable cells and cell debris. A total of 10,000 events were
analyzed for each variant per experiment.
For independent analyses of KV2.1 total expression, frozen
aliquots of electroporated cells were thawed, cultured for 24 hours,
and then directly harvested with Accutase, without cell-surface
labeling. Percent positive variant-expressing cells were normalized
to WT-expressing cells tested on the same day. Histograms were
aligned to correct for between-run variability in fluorescence inten-
sity; y-axes were uniformly set across conditions.
Cell-Surface Biotinylation and Immunoblotting
Frozen aliquots of CHO-K1 cells electroporated with WT or vari-
ant KV2.1 channels were thawed and grown under the same condi-
tions used for automated patch clamp recording. Cell-surface
biotinylation and immunoblotting were performed as previously
described,7,14 60 to 72 hours postelectroporation, using mouse anti-
KV2.1 (1:250; K89/34, Antibodies Incorporated), mouse anti–
transferrin receptor (1:500; H68.4, Thermo Fisher Scientific),
rabbit anticalnexin (1:250; H70; Santa Cruz Biotechnology, Santa
Cruz, CA), Alexa Fluor 680–goat antirabbit IgG (1:20,000; Jackson
ImmunoResearch, West Grove, PA), and Alexa Fluor 790–goat
antimouse IgG (1:20,000, Jackson ImmunoResearch) antibodies.
Normalized total, surface, and surface/total protein ratio
results were derived from 3 independent experiments. Calnexin
immunoreactivity was present in total protein lysates and absent
from the cell-surface fraction, confirming the selectivity of biotin
labeling for cell-surface protein.
Data Analysis
Data were analyzed using DataController384 V1.2.1 (Nanion Tech-
nologies), SigmaPlot 2000 (Systat Software, San Jose, CA), Prism
(GraphPad Software, San Diego, CA), and OriginPro 2018
(OriginLab, Northampton, MA). Variants were compared to WT
using 1-way analysis of variance (ANOVA) with Dunnett post hoc
comparisons or unpaired t tests. Normalizations and statistical com-
parisons to WT were conducted per plate (for electrophysiology) or
per experiment (for protein expression) to account for potential batch
effects. For voltage dependence in coexpression experiments, obtained
parameters (V1/2 or k) could not be subject to percentile normalization
(multiple batches); thus, average values of WT and each variant were
compared using Brown–Forsythe andWelch ANOVA with Dunnett
T3 multiple comparisons. Data fits with Boltzmann’s equation were
done for each individual cell using nonlinear curve fitting inOriginPro
2018; solid fit lines represent fits of averaged data.Whole-cell currents
normalized for membrane capacitance are expressed as
mean  standard error of the mean.
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Principal component analysis (PCA) was performed using
ClustVis,20 with principal components (PCs) calculated using
the Nipals algorithm. Six variables (homomeric) were compared:
Ipeak density, V1/2 and k for activation and inactivation, and cell-
surface/total expression ratio; all were normalized with respect to
WT by percentile value or z score. Spearman nonparametric cor-
relational analysis was performed using the leading variables from
PCA with number of seizure types and age at onset.
Results
KCNB1 Variant In Silico Analysis and Clinical
Phenotypes
KCNB1 variant residues reported here all show a high degree
of evolutionary conservation (Fig 1A) and are located mainly
in the transmembrane domains of KV2.1 (see Fig 1B, C).
S202, T210, R306, and R312 are located in the voltage-
sensing domain.21 R325 and E330 are in the S4–S5 linker,
critical for electromechanical coupling between the voltage-
sensing and pore domains.22 W370, P385, K391, and F416
are in the pore domain, with V378 and G381 located within
the selectivity filter.23 Truncation variants at Y274 and Y533
are not predicted to undergo nonsense-mediated mRNA
decay, as the premature stop codons are located in the last
exon, and are likely to generate truncated proteins. All
disease-associated (pathogenic/likely pathogenic) variants had
a scaled Combined Annotation Dependent Depletion score
of >22, indicating they rank among the top 1% of deleterious
variants with respect to all possible single nucleotide variants
in the reference genome (Supplementary Table 1).24
FIGURE 1: KCNB1 variants identified in individuals with developmental and epileptic encephalopathy. (A) Evolutionary conservation
of KV2.1 shown by multiple sequence alignment of KV2.1 species orthologues (Clustal Omega
39); secondary structural elements are
illustrated above the sequences. KV2.1 variants are shaded in red (missense) and yellow (nonsense). (B) Schematic view of the entire
KV2.1 subunit and the variants in the membrane, modified from Protter plot of Q14721 (KCNB1_Human).
40 (C) Locations of variants
(color-coded) mapped onto crystal structure of KV2.1/Kv1.2 chimera (PDB2R9R),
21 featuring a top view and a side view across a
lipid bilayer. Pore domain is highlighted in white; 2 variants (S457R and Y533X) are not depicted, because their location in the distal
C-terminus is not available in crystal structure. KcsA = K channel of streptomyces A.
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Clinical phenotypes summarized in Supplementary
Table 1 include DEE in 28 patients and other NDDs in
4 patients. Among those with NDDs, 1 had a single seizure
and 3 had no history of seizure at last reported follow-up
at ≤6 years of age. Phenotypes for novel variants reported
in Supplementary Table 1 are consistent with previous
reports.7–14 Supplementary Table 1 also includes variants
from previous clinically focused reports,11,16 summarized
here for completeness, with updates when available. In
total, there are 17 pathogenic/likely pathogenic variants
from 27 individuals, including several recurrent variants
(T210M × 3, R306C × 6, R312C × 2, R312H × 2,
E330D × 2, V378A × 2, P385T × 2, F416L × 3).
Consequences of KV2.1 Variants on Current
Density
To screen for functional consequences of the KCNB1 vari-
ants, we recorded whole-cell currents in voltage clamp mode
of CHO-K1 cells transiently expressing WT or variant KV2.1
channels using the SyncroPatch 768PE automated patch
clamp platform (see Fig 2A). Previous studies showed feasibil-
ity of this approach to study channel properties of KV2.1 and
the closely related KV7.1 channel encoded by KCNQ1.
14,25,26
In addition, we also tested on this platform the T374I variant
that we previously characterized by manual patch clamp
recording,7 and reproduced the loss-of-function phenotype
(see Fig 2B; p < 0.001, unpaired t test @ +60mV vs WT).
This further validates use of this platform to screen for KV2.1
dysfunction.
KV2.1 channels are a tetrameric assembly of 4 alpha
subunits encoded by KCNB1. When singly expressed in
CHO cells, the KV2.1 channels form a homomeric configura-
tion of 4 WT or 4 variant subunits. In the homomeric config-
uration, the majority of the KV2.1 variants (13/19) exhibited
low K+ conductance (loss of function; see Fig 2C, red),
whereas the remaining variants displayed moderate K+ con-
ductance (partial loss of function; blue) or K+ conductance
similar to WT (gray). The degree of loss of function was con-
sidered “partial” if Ipeak density was reduced 50 to 70% rela-
tive to WT and “severe” if >75%. Averaged whole-cell
current density traces for KV2.1 WT and representative vari-
ants are displayed to show diversity in current density (see
Fig 2C, right). Averaged whole-cell Ipeak density traces for all
KV2.1 variants are shown in Figure 3.
KCNB1 DEE is associated with de novo heterozy-
gous variants. Thus, an individual has KV2.1 subunits
produced from both WT and variant alleles. To determine
the effect of the KCNB1 variants in a condition resem-
bling heterozygosity in the patient, we coelectroporated
each variant with WT channels at a 1:1 equimolar ratio.
In the coexpression configuration (WT + variant), many
variants exhibited Ipeak density similar to cells transfected
with WT + WT channels, suggesting that these variants
can be rescued by WT coexpression. In contrast, W370R,
P385T, and F416L exhibited significantly lower Ipeak den-
sity compared to WT + WT cells (see Fig 2D, bars in
red). These variants also showed lower Ipeak density when
compared to cells transfected with half the amount of WT
plasmid (0.5× WT), suggesting a dominant-negative inter-
action of the variant with WT subunits. R306C and
V378L exhibited partial loss of function (bars in tur-
quoise) similar to 0.5× WT. Averaged current traces for a
subset of variants are displayed (see Fig 2D, right). Com-
plete statistical information including number of cells and
p values are shown in Supplementary Table 2, and nor-
malized traces are shown in Figure 3.
Total Protein Expression of KV2.1 Variants
To test whether loss-of-function phenotypes with impaired
current density were due to less channel protein, we evaluated
total expression levels for KV2.1 variants by immunoblotting
and/or immunocytochemistry–flow cytometry (ICC-FC)
using frozen aliquots of the same cells tested by electrophysiol-
ogy. In the homomeric configuration, population analyses of
KV2.1-positive cells confirmed that KCNB1 variants with
severe loss-of-function phenotypes had less KV2.1 protein
compared to WT (see Fig 2E, G). The same variants
coexpressed 1:1 with WT showed similar results. However,
correlational analyses of current density and total protein
expression showed no relationship between parameters in
either homomeric (R2 = 0.16, p = 0.22, Pearson correlation)
or coexpression conditions (R2 = 0.0003, p = 0.96; see Fig 2F,
H). Variants not shown in Figure 2E and G were tested by
immunoblotting (Fig 4E–G).
Expression Analysis of KV2.1 Variants: Cell-
Surface Trafficking
Presence at the cell-surface is critical for voltage-gated ion
channel function, and some variants may interfere with
KV2.1 cell-surface expression. Cell-surface and total expression
were simultaneously examined using ICC-FC. An extracellu-
lar hemagglutinin (HA)-epitope tag enabled discrimination of
cell-surface and total KV2.1 fractions, allowing rapid determi-
nation of cell-surface expression. A substantial population of
WT KV2.1 reached the cell-surface, with a mean surface/total
expression ratio > 0.8 (see Fig 4A, B), indicating highly effi-
cient cell-surface trafficking as previously shown.29,30 The
majority of the variants (13/19) exhibited deficits in cell-
surface expression of KV2.1, potentially explaining the loss of
K+ conductance observed by electrophysiology (see Fig 2C).
The nonpathogenic variants (R325Q, S457R) exhibited cell-
surface and total expression indistinguishable from WT (see
Fig 4). Cross-validation of select variants (T210K/M, R312C,
R325Q/W, V378A, K391N) with cell-surface biotinylation
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followed by immunoblotting produced largely congruent
results. The observed reduction in protein expression for some
variants that was not observed by ICC-FC is likely due to the
time difference at which the proteins were analyzed. It is pos-
sible that during the extended time (an extra 24–36 hours
compared to the ICC-FC experiment), variants may have trig-
gered misfolded protein responses, which may slow down
protein translation or induce cell death.
S202F, located near the HA-epitope site (amino acid
220), likely had altered immunoreactivity, considering the
lack of anti-HA signal but intact current density of S202F.
The substituted phenylalanine may result in steric hindrance,
preventing HA antigen–antibody interaction. For the
T210K/M variants, also located nearby the HA-tag site,
immunoblotting of nontagged T210K/M confirmed lower
cell-surface expression (see Fig 4A, B, E–G), consistent
FIGURE 2: High-throughput functional screening of KV2.1 variants. (A) Screenshot of automated whole-cell current recordings from
CHO-K1 cells transiently expressing KV2.1 channels, with 16 individual cell recordings shown on the right blue traces. Voltage protocols
used for functional studies are depicted in the box; red arrowheads indicate time-points of current measurement. I-V = current–voltage.
(B) Validation of automated patch clamp recordings of KV2.1 channels. Averaged KV2.1 wild-type (WT) and T374I variant (previously
published by our group usingmanual patch clamp) current–voltage relationships andwhole-cell current density traces show a similar loss-
of-function phenotype for the T374I variant. (C, D) Comparison of peak current (Ipeak) density of KV2.1 variants in homomeric and
coexpression (withWT) configuration (red bars: p < 0.001 vsWT, p < 0.05 vs 0.5 × WT; turquoise bars: p < 0.05 vsWT; 1-way analysis of
variance Dunnett multiple comparisons). Averaged whole-cell current traces of selected variants are shown on the right; endogenous
current recorded from nontransfected CHO-K1 cells were subtracted offline. Red arrowheads denote the time of Ipeak measurement. For
coexpression configuration, KV2.1 variants were coexpressed with WT by electroporation of equimolar amount of DNA. (E, G) Protein
expression analyses of variants by flow cytometry in the homomeric (left) and coexpression (right) configuration confirm KV2.1 protein
expression in variant-expressing cells, in particular for the ones with severely reduced current density, albeit with differing degrees of
severity. Data are shown in histograms aligned to correct for between-run variability in fluorescence intensity; y-axes were uniformly set
at a maximum of 250 and 350 event counts (for G and E, respectively) across conditions. (F, H) Correlation of Ipeak density and protein
expression by percentage KV2.1-positive cells, in either homomeric or coexpression configuration, did not reach statistical significance
(p= 0.22 and 0.96, respectively; Pearson correlation).
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with loss-of-function phenotypes in homomeric configura-
tion (see Fig 2C).
The 2 truncation variants, Y274fsX36 and Y533X, were
also tested for expression, despite lacking the epitope site for
anti-Kv2.1–Alexa 647 (amino acids 837–853). The Y274fsX
variant had no cell-surface HA signal (see Fig 4D). However,
in a subsequent experiment, permeabilization prior to anti-HA
incubation revealed abundant total expression, suggesting a
trafficking defect for Y274fsX36. Y533X exhibited cell-surface
HA immunoreactivity (see Fig 4D), indicating that truncated
Y533X proteins reach the plasmamembrane.
Voltage Dependence of Channel Activation and
Inactivation
Voltage dependence of channel activation and inactivation was
assessed for KV2.1 variants with sufficient K
+ conductance to
reliably measure these parameters. In the homomeric configu-
ration, several variants exhibited altered voltage dependence of
channel activation and inactivation when compared to WT
(Table). S202F and R312H exhibited depolarizing shifts in
their V1/2 for both channel activation and inactivation (see
Fig 5A) and larger slope factors, suggesting a decrease in voltage
sensitivity for channel inactivation. Y533X induced a dep-
olarizing shift in V1/2 of activation without affecting channel
inactivation (see Table). In contrast, R325W caused hyp-
erpolarizing shifts in the V1/2 values for both channel activation
and inactivation (see Fig 5A).
When coexpressed with WT, the effects of R312H
on channel activation and inactivation were abolished,
suggesting rescue by WT subunits. Coexpression with
WT channels prevented the depolarizing shift in activation
due to S202F, but did not alter the effects on inactivation
(see Fig 5B, Table). Hyperpolarizing shifts in V1/2 for acti-
vation and inactivation caused by R325W were still evi-
dent in the presence of WT, albeit with smaller
magnitude. Although T210K was nonfunctional as a
homotetramer, it caused a hyperpolarizing shift in inacti-
vation V1/2 when coexpressed with WT. A complete sum-
mary is presented in the Table.
Functional Effects of Nonpathogenic Variants
Two likely nonpathogenic variants (R325Q, S457R) were
included in functional assays, with experimenters blinded
to this status. R325Q was present as a singleton variant
(minor allele frequency [MAF] = 3.983e-06) in the genome
aggregation database (gnomAD), which is devoid of indi-
viduals with severe pediatric disease.27 R325Q was indis-
tinguishable from WT in contrast to the disease-associated
R325W variant, which induced changes in both channel
activation and inactivation (see Fig 5).
S457R was classified as nonpathogenic based on inheri-
tance from an unaffected parent and presence of S457R as a
singleton variant (MAF = 3.983e-06) in gnomAD.27 In the
homomeric configuration, S457R was indistinguishable from
FIGURE 3: Averaged current density traces normalized to the maximal peak, showing averaged whole-cell currents recorded
from CHO-K1 cells transiently expressing homomeric wild-type (WT) or variant KV2.1, or coexpressing WT + variant KV2.1 and
normalized to the maximum peak current at +60mV. Traces were normalized to peak current to enable comparison of gating
behaviors among variants with divergent current density. Horizontal scale bar represents 200 milliseconds.
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FIGURE 4: Total and cell-surface protein expression levels of KV2.1 variants. (A) Representative dot-plots of flow cytometry
analyses of CHO cells expressing KV2.1 tagged with hemagglutinin (HA)-epitope at the extracellular site between S1–S2 linker
regions; anti–HA-Alexa 488 and anti–KV2.1-Alexa 647 antibodies were used to probe the cell-surface and intracellular KV2.1,
respectively. Population in turquoise (HA+/KV2.1
+) denotes KV2.1 located at the cell surface, whereas the dots in red (HA
+/
KV2.1
−) indicate expressed KV2.1 protein located intracellularly. Wild-type (WT) and nontransfected CHO cells (negative control)
are shown at the top left for comparison. Nontransfected CHO cells underwent the entire immunocytochemistry labeling
protocol. Asterisks denote variants with intact cell-surface trafficking, ie, S/T ratio > 0.3. (B) Expression level comparisons of
KV2.1 variants to that of WT (white bars) revealed reduced cell-surface trafficking of variants. Cell-surface expression is shown in
turquoise and the total expression in red. (C) Correlational analyses of surface-to-total expression level ratio and homomeric
peak current (Ipeak) density (values in % WT) result in R
2 = 0.41 and p = 0.006 by Pearson correlation. (D) Analyses of 2 truncation
variants, devoid of the epitope site for anti–KV2.1-Alexa 647, further validate the assay. The Y274fsX36 variant fails to reach the
cell surface. In contrast, for Y533X, the population in green (HA+/KV2.1
−) denotes KV2.1 expressed and reaching the cell surface,
yet unable to be detected by the anti–KV2.1-Alexa 647 antibody due to the absent epitope. (E, F) Cross-validation analyses of
select KV2.1 variants for cell-surface and total protein expression. CNX = calnexin; TfR = transferrin receptor; S/T = surface/total
ratio; LL = lower left; LR = lower right; UL = upper left; UR = upper right. (G) Quantification of Western blot analyses confirms
similar expression pattern as immunocytochemistry–flow cytometry assay.
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WT. However, there was a hyperpolarizing shift in voltage
dependence of activation when S457R was coexpressed with
WT. S457 is subject to post-translational phosphorylation,
and dephosphorylation of KV2.1 is associated with
hyperpolarizing shifts in voltage-dependent gating.28 The
observed difference in voltage dependence of activation may
reflect differences in phosphorylation state between the vari-
ant (nonphosphorylated residue 457) and WT subunits
(phosphorylated residue 457) under our experimental condi-
tions, which require intracellular sodium fluoride, a phospha-
tase inhibitor, for gigaohm seal formation.
Genotype–Phenotype Analyses of KV2.1 Variants
To visualize the relationship among various parameters, we
performed PCA using 6 variables measured in the homomeric
configuration: Ipeak density, V1/2 and k for activation and
inactivation, and cell-surface/total expression ratio (Fig 6).
The top 3 leading dimensions for PC1 were Ipeak density
(0.61), cell-surface/total expression ratio (0.62), and V1/2 for
activation (−0.28); for PC2, they were Ipeak density (0.62),
and inactivation V1/2 (0.47) and k (0.49). Plotting PC1 versus
PC2 separated nonpathogenic (R325Q, S457R, WT) from
pathogenic variants with 95% confidence. However, it was
not possible to separate the pathogenic variants by clinical
classification.
In addition, we performed correlational analyses
with quantifiable clinical phenotypes and the leading vari-
ables identified by PCA: conductance and cell-surface/total
expression ratio (see Fig 6B–E). Among these parameters,
we identified a single correlation between the number of
seizure types and conductance (R2 = 0.19; p < 0.02, Spear-
man), with low/no conductance associated with a more
complex clinical presentation that included multiple sei-
zure types. Conversely, variants with some level of
preserved conductance (>0.2 of WT) had only 1 to 2 sei-
zure types, indicative of a less complex clinical
presentation.
Discussion
KV2.1 Loss of Function in KCNB1 DEE
Here we report functional studies of 19 KCNB1 variants,
including 17 likely pathogenic variants identified in individ-
uals with DEE or other NDDs, and 2 presumed nonpatho-
genic variants present in the gnomAD database, which
excludes severe pediatric disease.27 High-throughput electro-
physiological and biochemical analysis of KV2.1 variants
expressed in CHO-K1 cells revealed partial or near-complete
loss of function as a common mechanism, consistent with
prior manual electrophysiology.7–9 The molecular mecha-
nisms underlying loss-of-function phenotypes included lower
Ipeak density due to low total and/or cell-surface KV2.1
expression, and shifts in voltage dependence of activation
and inactivation.
The majority of variants exhibited significantly lower
Ipeak density when expressed as homotetramers. However,
coexpression with WT subunits normalized Ipeak density for
many variants. Rescue by WT subunits suggests that variant
subunits traffic to the cell surface as part of a heteromeric
assembly, raising the possibility of rescue by molecular chap-
erones. In contrast, coexpression of some variants (R306C,
V378L) with WT resulted in lower Ipeak density, approxi-
mating 0.5× WT, suggesting that although the mutant
subunits cannot be rescued, they do not interfere with cell-
surface expression of WT. Coexpression of other variants
(W370R, P385T, F416L) with WT resulted in Ipeak den-
sity < 0.5× WT, suggesting a dominant-negative effect on
cell-surface expression of WT subunits.
FIGURE 5: Voltage dependence of activation/inactivation of KV2.1 variants. Voltage-dependent channel activation (open circles)
and inactivation (solid circles) curves obtained from selected homomeric and coexpression KV2.1 variants are compared to wild
type (WT; black circles). Solid lines represent averaged data fits with the Boltzmann equation. Numerical values of voltage for
half-maximal channel activation and slope factor for the other variants are listed in the Table.
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TABLE. Biophysical Properties of KV2.1 Variants Singly or Coexpressed with WT
Configurations
or Variants
Voltage Dependence of Activation Voltage Dependence of Inactivation
V½ k V½ k
WT −4.6  1.0 13.0  0.4 −35.5  2.6 7.5  0.6
S202F 24.3  3.8, p < 0.001
(n = 14)a
16.4  1.7, p > 0.189 (n = 14) 2.7  1.2, p < 0.001 (n = 30)a 8.8  0.4, p < 0.001
(n = 30)a
R312H 28.1  1.5, p < 0.001
(n = 21)a
18.2  1.0, p < 0.001 (n = 21)a −0.1  2.3, p < 0.001 (n = 18)a 8.5  0.7, p < 0.001
(n = 18)a
R325Q −5.0  2.5, p > 0.884 (n = 18) 14.8  1.2, p > 0.804 (n = 18) −39.6  1.8, p > 0.704 (n = 17) 7.1  0.4, p > 0.083 (n = 17)
R325W −23.4  3.9, p < 0.001
(n = 22)a
17.7  1.2, p > 0.033 (n = 22) −58.0  1.4, p < 0.001 (n = 25)a 5.7  0.2, p < 0.001
(n = 25)a
S457R −13.3  1.4, p > 0.050
(n = 25)
12.0  0.7, p > 0.952 (n = 25) −44.2  1.7, p > 0.543 (n = 38) 6.5  0.2, p > 0.418 (n = 38)
Y533X 13.0  3.6, p < 0.001 (n = 17)a 18.3  1.4, p < 0.001 (n = 17)a −45.7  2.6, p > 0.313 (n = 26) 6.8  0.6, p > 0.200 (n = 26)
WT + WT −7.3  0.9 12.9  0.9 −39.6  0.6 6.3  0.1
WT + S202F 1.3  3.1, p > 0.184 (n = 25) 22.2  0.8, p < 0.001 (n = 25)a −29.6  1.7, p < 0.001 (n = 54)a 10.4  0.4, p < 0.001
(n = 54)a
WT + T210K −10.8  1.3, p > 0.395
(n = 44)
13.1  0.5, p > 0.999 (n = 44) −46.2  1.3, p < 0.001 (n = 34)a 6.3  0.2, p > 0.999 (n = 34)
WT + T210M −6.9  1.7, p > 0.999 (n = 29) 12.9  0.9, p > 0.999 (n = 29) −43.3  2.4, p > 0.917 (n = 25) 6.5  0.3, p > 0.996 (n = 25)
WT + Y274fsX −7.1  4.0, p > 0.999 (n = 18) 14.5  1.1, p > 0.949 (n = 18) −40.2  1.6, p > 0.999 (n = 65) 5.7  0.2, p > 0.380 (n = 65)
WT + R306C −15.9  3.7, p > 0.435
(n = 11)
15.3  2.2, p > 0.989 (n = 11) −44.9  3.2, p > 0.847 (n = 22) 9.0  0.6, p < 0.003
(n = 22)a
WT + R312C −9.1  1.3, p > 0.989 (n = 35) 13.4  0.5, p > 0.999 (n = 35) −42.0  1.3, p > 0.850 (n = 27) 6.0  0.1, p > 0.946 (n = 27)
WT + R312H 0.1  2.7, p > 0.198 (n = 31) 14.3  0.7, p > 0.776 (n = 31) −38.7  1.5, p > 0.999 (n = 78) 7.7  0.4, p > 0.010 (n = 78)
WT + R325Q −10.7  1.4, p > 0.527
(n = 43)
12.8  0.6, p > 0.999 (n = 43) −43.4  1.7, p > 0.531 (n = 32) 5.9  0.2, p > 0.957 (n = 32)
WT + R325W −14.3  1.7, p < 0.011
(n = 39)a
16.1  1.0, p > 0.077 (n = 39) −51.9  1.5, p < 0.001 (n = 35)a 5.9  0.2, p > 0.957 (n = 35)
WT + E330D −12.4  2.3, p > 0.529
(n = 18)
15.3  1.4, p > 0.825 (n = 18) −40.4  2.3, p > 0.999 (n = 52) 7.4  1.0, p > 0.987 (n = 52)
WT + W370R −3.5  3.3, p > 0.986 (n = 12) 16.4  1.8, p > 0.663 (n = 12) −38.9  2.9, p > 0.999 (n = 26) 6.9  0.4, p > 0.813 (n = 26)
WT + V378A −7.5  1.4, p > 0.999 (n = 29) 13.3  0.5, p > 0.999 (n = 29) −41.4  1.2, p > 0.976 (n = 32) 5.6  0.2, p > 0.159 (n = 32)
WT + V378L −5.8  4.8, p > 0.999 (n = 20) 16.0  1.2, p > 0.298 (n = 20) −46.4  1.9, p > 0.022 (n = 61) 7.5  0.3, p < 0.003 (n = 61)
WT + G381R −9.4  2.7, p > 0.999 (n = 27) 14.2  1.0, p > 0.916 (n = 27) −41.2  1.4, p > 0.995 (n = 62) 6.3  0.5, p > 0.999 (n = 62)
WT + P385T −6.7  4.1, p > 0.999 (n = 11) 14.9  1.2, p > 0.850 (n = 11) −40.6  2.1, p > 0.999 (n = 43) 6.9  0.5, p > 0.958 (n = 43)
WT + K391N −9.4  1.2, p > 0.947 (n = 44) 12.6  0.4, p > 0.999 (n = 44) −41.4  1.2, p > 0.977 (n = 39) 5.9  0.1, p > 0.492 (n = 39)
WT + F416L −3.1  3.7, p > 0.988 (n = 16) 15.6  1.1, p > 0.388 (n = 16) −39.5  1.6, p > 0.999 (n = 48) 7.3  0.4, p > 0.175 (n = 48)
WT + S457R −18.9  3.0,
p < 0.019 (n = 22)a
14.1  1.0, p > 0.989 (n = 22) −42.0  1.6, p > 0.960 (n = 42) 5.9  0.2, p > 0.959 (n = 42)
WT + Y533X −11.6  1.7, p > 0.384
(n = 42)
14.8  0.8, p > 0.468 (n = 42) −43.0  1.4, p > 0.432 (n = 65) 6.0  0.2, p > 0.998 (n = 65)
Singly expressed variants with at least 10pA/pF are included; n = the number of cells recorded.
aValues that differ from the respective WT condition (Dunnett T3 multiple comparisons).
k = slope factor; V½ = voltage for half-maximal channel activation; WT = wild type.
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Several variants encoded functional KV2.1 channels
with Ipeak density indistinguishable from WT, but with
defects in voltage dependence. Depolarizing shifts in V1/2
for both activation and inactivation were observed for
S202F and R312H, resulting in loss of function due to
impaired channel opening in a physiological voltage range.
Conversely, R325W had hyperpolarized shifts in V1/2 for
activation and inactivation. Although this likely results in
enhanced channel opening at physiological voltages, the
corresponding shift in the voltage dependence of inactivation
limits channel availability, suggesting overall loss of function.
Coexpression of WT channels to approximate heterozygosity
resulted in attenuated or altered voltage dependence. This
may be explained by variable populations of WT + WT,
WT + variant, and variant+variant channels. The presence of
significant voltage dependence phenotypes specific to
coexpression conditions (activation k for WT + S202F or
activation V1/2 for WT + S457R) suggests that some variants
coassemble with WT subunits as heterotetramers.
Comparison of Same-Site Substitutions
The importance of experimental validation is highlighted by
pairwise comparison of substitutions of different amino acids
at the same position (T210K/M, R312C/H, R325Q/W,
and V378A/L). The T210K/M variants resulted in loss
of K+ conductance and cell-surface KV2.1 expression. T210
is a critical residue forming the S1–pore interface.31,32
A hydroxyl group is required at this position for channel
function.32 Thus, substitution with either lysine or methio-
nine would be incompatible with channel function. In con-
trast, R312H and R312C resulted in partial and severe loss
of conductance, respectively, which was opposite of the in
silico consequence prediction that suggested R312H would
be more deleterious than R312C (see Supplementary
Table 1). Retaining a positive charge at this position in the
S4 segment by substituting histidine may lessen severity rela-
tive to a charge-neutralization cysteine substitution. Similarly,
the R325Q/W variants differed in their voltage dependence,
with R325Q retaining WT-like behavior, consistent with
nonpathogenicity. This suggests that substitution of R325
with a bulky hydrophobic tryptophan may alter electrochem-
ical coupling between S4–S5 and the S6 segment,33 whereas
glutamine is tolerated.
Both the V378A/L variants resulted in loss of K+ con-
ductance in the absence of WT subunits. V378L exhibited
modest cell-surface expression, whereas the V378A variant
was absent, suggesting discrete mechanisms underlying loss
of K+ conductance for these variants. Leucine is present at
the equivalent position in KV3 and KV4 channels, indicating
that this substitution is structurally tolerable and maintains
K+ selectivity, although it likely alters conductance.34,35 Con-
versely, substitution with alanine has been shown to disrupt
ion selectivity and affect channel stability.35 Previous studies
of the V378A variant in CHO-K1 and COS-7 cells showed
FIGURE 6: Principal component analyses of KV2.1 variants. (A) Experimental data for biophysical and protein expression analyses
were transformed with respect to wild type (WT), to generate eigenvector-based multivariate analyses, and plotted using
ClustVis.20 Nipals principal component analysis is used to calculate principal components, with ellipses depicting 95% confidence
interval. Each axis explains 61% and 24.1% of the total variance (x and y, respectively); n = 20 data points. Six variables
measured in the homomeric condition were used: peak current (Ipeak) density, voltage for half-maximal channel activation (V½)
and slope factor (k) for activation and inactivation, and protein expression cell-surface/total ratio. The top 3 leading dimensions
(variable) for principal component 1 (PC1) were Ipeak density (0.61), cell-surface/total expression ratio (0.62), and V1/2 for
activation (&minus;0.28); for PC2, they were Ipeak density (0.62), inactivation V1/2 (0.47), and k (0.49). Nonpathogenic variants
and WT (in green) are separable from the pathogenic variants (red, blue). DEE = developmental epileptic encephalopathy;
NDD = neurodevelopmental disorder. (B–E) Correlational analysis of quantifiable clinical parameters and the leading functional
parameters identified in this study. Conductance values normalized to that of WT and surface-to-total protein expression ratio
were used for analyses. R2 values are noted for each plot (***p < 0.02, Spearman).
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impaired expression that could be rescued by the KV2 inhibi-
tor GxTx, suggesting enhanced internalization and degrada-
tion as a possible mechanism.9 Consistent with this, we
observed robust total expression of V378A at 24 hours post-
transfection (see Fig 4), whereas there was little V378A
expression at 72 hours (see Fig 4E–G).
High-Throughput Variant Characterization
Pipeline
One goal of this study was to optimize electroporation and
automated planar patch clamp technologies for high-
throughput characterization of KCNB1 variants identified by
clinical genetic testing, making it feasible to rapidly character-
ize new variants. Moreover, the ICC-FC assay enables high-
throughput evaluation of cell-surface and total protein
expression for further delineation of pathogenic mechanisms.
Efficient functional characterization of ion channel variants is
critical to realize the precision medicine goal of rapid, defini-
tive precision diagnosis and targeted treatment based on the
specific genetic variant.
Utility of Functional Characterization for Clinical
Genetic Testing
Based on American College of Medical Genetics and Geno-
mics guidelines, evidence of a deleterious effect on protein
function can be considered “strong” evidence for pathogenic-
ity, given the functional assay is robust and validated.3 Electro-
physiology is the gold standard for characterizing the effects of
ion channel variants, and is a well-validated, robust approach.
In contrast, in silico evidence based on pathogenicity predic-
tion algorithms are only considered “supporting” evidence,
insufficient when considered alone. Functional variant charac-
terization, both in channelopathies and in other disorders, has
untapped potential to provide diagnostic benefit for weighing
variant pathogenicity. Functional characterization of a series of
KCNB1 variants can serve as a reference dataset for genetic test
interpretation in newly diagnosed patients, and provide addi-
tional evidence for reclassification of variants previously classi-
fied as variants of uncertain significance.
The KCNB1 variants R325Q and S457R provide
examples of how functional variant characterization can
provide useful information. R325Q is a rare population
variant that exhibited similar functional characteristics to
WT channels, demonstrating that glutamine substitution
at R325 is tolerated. However, R325W had significant
functional defects as a homotetramer and when
coexpressed with WT (see Fig 2C, D), supporting this
variant as potentially pathogenic. S457R was initially
identified by clinical genetic testing in a child with DEE,
but was later found to be inherited from an unaffected
parent. Prior to parental testing, we performed electro-
physiological characterization of S457R and found no
deleterious effect on protein function, consistent with
nonpathogenicity. PCA allowed reliable separation of the
nonpathogenic group (R325Q, S457R, WT) from the
other 17 variants studied, highlighting the viability of
functional screening to differentiate nonpathogenic ver-
sus pathogenic variants with high confidence (95%).
Genotype–Phenotype Correlations
Another goal of our study was to assess potential correlations
between KV2.1 channel dysfunction and clinical severity.
Although the clinical phenotypes of DEE and other NDDs
were not distinguished by PCA, it is possible that the NDD
cases (3–6 years of age at the time of reporting) will go on to
develop epilepsy, as there are at least 2 DEE cases with seizure
onset in adolescence (see Supplementary Table 1). We identi-
fied a correlation between conductance and the number of
seizure types, indicating that variants with preserved function-
ality are associated with less complex epilepsy. However, due
to the higher likelihood of genetic testing in complex epilepsy
cases, our cohort is biased toward the more severe end of the
spectrum. Characterization of additional variants across a
broad clinical spectrum may help establish clearer genotype–
phenotype correlations. Alternatively, the underlying patho-
genic mechanisms may require more complex experimental
systems, and/or final expression of the clinical phenotype can
be influenced by other genetic, epigenetic, or environmental
modifiers. The variable severity observed among patients with
the same recurrent variant is consistent with other factors con-
tributing to clinical presentation.
Limitations of High-Throughput Functional
Screening
Despite the aforementioned strengths of functional evaluation
in a heterologous expression model, there are some limitations.
Some KV2.1 variant effects detected in our study may become
more or less pronounced in neurons. For example, variant and
WT alleles are coexpressed in individuals with KCNB1 DEE,
which is associated with heterozygous variants. However, in
CHO-K1 cells, coexpression withWT sometimes masked var-
iant effects. This highlights a difference between heterologous
expression versus the nervous system and suggests that
homomeric expression provides a more robust assay. In neu-
rons, a population of nonconducting KV2.1 clustered at plasma
membrane–endoplasmic reticulum junctions operates as a
docking site for membrane proteins,30 a function that is not
assessed in our system. In addition, the effect of variants that
alter binding site affinity for interacting proteins like KChAP,
AMIGO, and KCNE1-336–38 may not be detected if inter-
acting proteins are not present at relevant levels in CHO-K1
cells. Hence, additional characterization of variants in more
complex experimental systems will be necessary for complete
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understanding of disease mechanisms in neurons and other
specialized cells where KV2.1 is a significant contributor.
Conclusions
Efficient characterization of KCNB1 variants can provide
the precision diagnoses required for precision medicine.
Many of the disease-associated KCNB1 variants (14/17)
exhibited phenotypes that ultimately result in a channel
hypofunction, through (1) decreased K+ conductance,
(2) altered voltage dependence, (3) reduced protein expres-
sion, or (4) altered cell-surface trafficking. Classification of
KCNB1 variants into categories of defects suggests that
molecular chaperones to increase cell-surface expression
may be a suitable therapeutic strategy for some, whereas
subtype-selective activators of KV2.1 may be a viable ther-
apy for others. Alternatively, antisense oligonucleotide or
gene therapy approaches that increase expression may hold
promise for treatment of KCNB1 DEE.
Note in proof: An additional clinical paper describ-
ing KCNB1 DEE was recently published. Bar, C, Barcia,
G, Jennesson, M, et al. Expanding the genetic and pheno-
typic relevance of KCNB1 variants in developmental and
epileptic encephalopathies: 27 new patients and overview
of the literature. Human Mutation. 2019; 1–12. https://
doi.org/10.1002/humu.23915.
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